Shareholders who purchased shares of EPIX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required ...

Researchers explored how Pluvicto is used in the community and academic settings and when given by oncologists or urologists.

Accurate calculation of prostate-specific antigen doubling time can be crucial for prostate cancer treatment decisions but is ...

Investigators report that estradiol works as well as luteinizing hormone–releasing hormone agonists for testosterone suppression and have a much better side-effect profile.

NEW YORK, NY / ACCESS Newswire / February 19, 2025 / If you suffered a loss on your ESSA Pharma Inc. (NASDAQ:EPIX) investment and want to learn ...

For patients with metastatic castration-resistant prostate cancer (mCRPC) unselected for homologous recombination repair (HRR ...

For patients with metastatic castration-resistant prostate cancer (mCRPC) unselected for homologous recombination r ...

Clarity Pharmaceuticals (ASX: CU6) ('Clarity' or 'Company'), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for ...

Exelixis’ next-generation tyrosine kinase inhibitor zanzalintinib is being tested for colorectal cancer, renal cell carcinoma ...

PSA doubling time is an essential criterion for high-risk biochemically recurrent prostate cancer that should prompt treatment escalation.

Levi & Korsinsky, LLP notifies investors in ESSA Pharma Inc. ("ESSA Pharma Inc." or the "Company") of a class action securities ...

The latest figures on prostate cancer are shocking: it has officially overtaken breast cancer as the most commonly diagnosed ...